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Measurement of tumour and normal tissue perfusion in vivo in cancer patients will aid the clinical development of antiangiogenic and
antivascular agents. We investigated the potential antiangiogenic effects of the drug razoxane by measuring the changes in parameters
estimated from H2
15O and C
15O positron emission tomography (PET) to indicate alterations in vascular physiology. The study
comprised 12 patients with primary or metastatic renal tumours 43cm in diameter enrolled in a Phase II clinical trial of oral
razoxane. Perfusion, fractional volume of distribution of water (VD) and blood volume (BV) were measured in tumour and normal
tissue before and 4–8 weeks after treatment with 125mg twice-daily razoxane. Renal tumour perfusion was variable but lower than
normal tissue: mean 0.87mlmin
 1ml
 1 (range 0.33–1.67) compared to renal parenchyma: mean 1.65mlmin
 1ml
 1 (range 1.16–
2.88). In eight patients, where parallel measurements were made during the same scan session, renal tumour perfusion was
significantly lower than in normal kidney (P¼0.0027). There was no statistically significant relationship between pretreatment
perfusion and tumour size (r¼0.32, n¼13). In six patients scanned before and after razoxane administration, there was no
statistically significant change in tumour perfusion: mean perfusion pretreatment was 0.81mlmin
 1ml
 1 (range 0.46–1.26) and
perfusion post-treatment was 0.72mlmin
 1ml
 1 (range 0.51–1.15, P¼0.15). Tumour VD and BV did not change significantly
following treatment: mean pretreatment VD¼0.66 (range 0.50–0.87), post-treatment VD¼0.71 (range 0.63–0.82, P¼0.22);
pretreatment BV¼0.18mlml
 1 (range 0.10–0.25), post-treatment BV¼0.167mlml
 1 (range 0.091–0.24, P¼0.55). Tumour
perfusion, VD and BV did not change significantly with tumour progression. This study has shown that H2
15O and C
15O PET provide
useful in vivo physiological measurements, that even highly angiogenic renal cancers have poor perfusion compared to surrounding
normal tissue, and that PET can provide valuable information on the in vivo biology of angiogenesis in man and can assess the effects of
antiangiogenic therapy.
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Razoxane, also known as ICRF 159 ((7)-1,2-bis(3,5-dioxopiper-
azin-1-yl) propane), is a chemotherapeutic agent, which inhibits
cell division in the premitotic and early mitotic phases of the cell
cycle (Sharpe et al, 1970). Antitumour activity with razoxane has
been reported in acute leukaemia, lymphomas, lymphosarcomas,
colorectal cancer, and head and neck carcinoma (Hellmann and
Burrage, 1969; Bakowski, 1976; Bellet et al, 1976; O’Connell et al,
1980). Inhibition of angiogenesis was noted in preclinical studies
(Hellmann and Burrage, 1969; Salsbury et al, 1970, 1974; Le Serve
and Hellmann, 1972). Hellmann and Burrage (1969) demonstrated
inhibition of metastases in implanted Lewis lung carcinoma
treated with razoxane. Salsbury et al (1970) found that the treated
tumours were less hyperaemic on histological examination
compared to controls, and instead of the network of poorly
defined vascular channels, treated tumours contained only a few
discrete blood vessels (Salsbury et al, 1970). Tumour vasculature
studies using X-ray angiography and carbon black studies showed
random, abnormal dilated vessels in untreated Lewis lung
carcinomas. Treated tumour vessels appeared discrete with a
regular vascular arrangement (Le Serve and Hellmann, 1972).
With the recent interest in chemotherapy agents with specific
antiangiogenic effects, razoxane has been reinvestigated and has
recently undergone a Phase II clinical trial in renal tumours
(Braybrooke et al, 2000). Metastatic renal cell carcinomas are
highly vascular, and neovascularisation due to tumour angiogen-
esis is a common feature (DeKernion, 1986; Sasaki, 1996). To
provide a specific assessment of the potential antiangiogenic effect
of razoxane in the Phase II trial, we used H2
15O and C
15O positron
emission tomography (PET) to measure a range of vascular
pharmacodynamic parameters. Received 21 March 2003; accepted 26 April 2003
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lPositron emission tomography is a noninvasive imaging
modality capable of quantifying physiologic and metabolic
processes in vivo. Techniques have been developed using
15O
labelled water and carbon monoxide to quantify regional perfu-
sion, fractional volume of distribution of water (VD) and blood
volume (BV) within tissues. The background to PET measure-
ments of vascular parameters is reviewed elsewhere (Anderson and
Price, 2002). Briefly, the rationale behind their use in the clinical
assessment of response to antiangiogenic agents is that the
protracted administration (i.e. weeks rather than hours) of a drug
that inhibits angiogenesis should lead to fewer blood vessels in
tumours. Fewer new blood vessels should result in a reduction in
perfusion (angiogenic areas of tumour are better perfused) and
blood volume (fewer vessels less blood). Although VD is a
nonvalidated parameter and has not yet been related to a
physiological parameter, it is determined simultaneously with
perfusion. Fractional volume of distribution of water is the
proportion of the region of interest in which the radioactive water
is distributed, for example, if VD¼0.5, only half of the volume is
perfused. Fractional volume of distribution of water is thought to
represent the proportion of viable tissue within a region of interest
(ROI; Anderson and Price, 2002). The PET techniques were
originally developed to measure perfusion and related parameters
in the brain and heart (Lammertsma et al, 1985; Araujo et al,
1991). They have subsequently been modified and used in tumours
(Wilson et al, 1992). Although tumour blood flow and its
modulation have been studied extensively in animal models, little
work has been carried out using this technique to measure tumour
perfusion in humans in order to evaluate therapeutic response. A
small study using PET to measure perfusion in two patients with
liver tumours before and after the administration of angiotensin II
found a reduction in perfusion in normal tissue, but no change in
the perfusion to tumours (Taniguchi et al, 1996). Recently, the
results of PET measurements of tumour blood flow before and
after administration of the antiangiogenic agent endostatin in a
Phase I trial have been published (Herbst et al, 2002). In the
endostatin trial, a statistically significant reduction in tumour
blood flow was measured using H2
15O PET 4 weeks after the start of
treatment.
The aim of this study was to quantify perfusion, VD and BV in
renal cell carcinoma in vivo before and after a course of razoxane
in patients enrolled in a Phase II trial (Braybrooke et al, 2000).
Antiangiogenic agents do not target established blood vessels and,
therefore, are not expected to induce regressions in tumours. It is
generally considered that protracted treatment will be required,
and disease stabilisation is considered a relevant end point for
assessing the clinical response of antiangiogenic agents. For these
reasons, it was hypothesised that surrogate markers of response at
the end of the first course of treatment (rather than hours after
administration of a single dose) were most likely to measure drug-
induced changes in vascular parameters. Based on the preclinical
findings on the effect of razoxane in animal studies (Salsbury et al,
1970; Le Serve and Hellmann, 1972), our hypothesis was that
following treatment with razoxane there would be a reduction in
perfusion, VD and BV of tumours as the hyperaemic and abnormal
vascular channels are replaced by fewer normal vessels.
METHODS
Patients
Patients were enrolled as part of a Phase II clinical trial of razoxane
conducted at the ICRF Medical Oncology Unit, Oxford. Patient
details are listed in Table 1. Inclusion and exclusion criteria for the
Phase II study are published elsewhere (Braybrooke et al, 2000).
Patients referred for PET scans also had a tumour mass greater
than 3cm in diameter (to ensure adequate sampling of PET scan
data) and had to agree to attend the Hammersmith Hospital on
two separate occasions for PET scans. Permission to carry out the
study was given by the Hammersmith Hospital NHS Trust Ethics
Committee and the Central Oxfordshire Research Ethics Commit-
tee. The Administration of Radioactive Substances Advisory
Committee gave authorisation for use of radionuclides. All patients
gave written informed consent.
Study design
Patients attended the Hammersmith Hospital as outpatients and
were scanned prior to and after 4–8 weeks of treatment with daily
oral razoxane (125mg b.d. ). Two measurements of perfusion and
BV were recorded at each session with the patient in the same
scanning position. Pretreatment measurements were compared
with known tumour phenotype characteristics. Changes in
perfusion, VD and BV after 4–8 weeks of treatment with razoxane
were recorded and compared with clinical response criteria, which
have been described in detail elsewhere (Braybrooke et al, 2000).
Scanning protocol
Prior to scanning, patients were cannulated with an arterial line
inserted into the radial artery. An i.v. line was inserted into an
accessible vein in the other arm. An ECAT 931 08/12 PET scanner
(CTI PET Systems, Knoxville, TN, USA) was used, which measures
15 transaxial planes in 0.65cm slices covering a 10.8cm axial field
of view. Patients were positioned according to the location of their
tumour on a CT scan, and the position recorded to use for the
Table 1 Patient details
Renal tumour lesion imaged Pretreatment tumour size
a (cm) Prescan tumour Postscan tumour Spleen Kidney
Patient 1 Pelvic recurrence 12 14 X
b X
Patient 2 Para-aortic nodes 4.6 2.7 X X
Patient 3 Primary renal mass 12.5 12 X X
Patient 4 Para-aortic nodal recurrence 5 3.8 X X X
Patient 5 Primary renal mass 12.7 12.5 X X X X
Patient 6 Lung metastasis 5 5X X
Patient 7 Mesenteric mass 6 7X X X X
Patient 8 Primary renal mass 7.0 7.5 X X X
Patient 9a Primary renal mass 7.5 9X X
9b Para-aortic nodal recurrence 5 3.5 X
Patient 10a Primary renal mass 8 7.5 X X
10b Para-aortic nodal mass 5 4.5 X
Patient 11 Primary renal mass 12 9X XX
Patient 12 Mediastinal nodes 3 3X
aThe pretreatment size of tumour was measured from the pretreatment CT scan by bidimensional measurements.
bX indicates that a particular tissue region could be analysed.
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lsecond scan to ensure that the pre- and post-therapy regions of
interest for analysis were the same. A 20-min transmission scan
using
68germanium was performed for attenuation correction.
Patients then received a bolus infusion of H2
15O at a dose of
600MBq via the intravenous line over 20s at a rate of 10mlmin
 1
followed by a 2-min saline flush. A total of 28 frames of PET
emission data were acquired (1 30s, 1 20s, 14 5s, 3 10s,
3 20s, 6 30s) starting approximately 30s before the infusion.
During this time, continuous arterial blood sampling was acquired
using an online BGO detector and automated pump at a rate of
5mlmin
 1 to measure the arterial input function (Ranicar et al,
1991). A discrete sample was also taken at the completion of the
scan for cross-calibration of the continuous data. The patient
positioning was maintained, and the H2
15O infusion and data
acquisition were then repeated after 15min. For the C
15O scans,
C
15O was inhaled through a loose fitting mask at a dose of
3MBqml
 1 and at a rate of 500mlmin
 1 for 6min. Static images
were then acquired at equilibrium 2min after the end of C
15O
administration. Discrete blood samples were acquired at 0, 2, 4 and
6min to measure the concentration of blood radioactivity. The
C
15O acquisition was repeated 10min after the conclusion of the
first scan. Emission and transmission data were reconstructed
using a Hanning filter with a cutoff frequency of 0.5U of the
reciprocal of the sampling interval of the projection data resulting
in an image resolution of 8.4 8.3 6.6mm
3 full-width at half-
maximum at the centre of the field of view. Images were
normalised for differences in detector efficiency, corrected for
photon attenuation, calibrated to absolute units of radioactivity
(kBqml
 1), and then transferred to a SUN SPARC Workstation for
processing and analysis.
Data analysis
Image visualisation and ROI analysis were performed using the
Clinical Applications Programming Package (CAPP) software (CTI
PET Systems, Knoxville, TN, USA). For each H2
15O perfusion study,
the dynamic images were summed over all time frames to generate
signal-averaged ‘Add’ images, which enabled the anatomy to be
visualised with improved signal-to-noise ratio. Since the C
15OB V
images are already summed static images, no further processing
was required to improve visualisation. The blood flow Add images
and BV images were compared with the pretreatment CT scan to
aid the localisation of the tumour and other normal organs. Region
of interests were then manually drawn on each transaxial plane of
the PET blood flow Add images and/or BV images to identify the
areas of tumour and normal tissue that were in the field of view.
Many of the large renal cell masses had areas of necrosis seen as
very low radiotracer accumulation. On the perfusion images, large
central macroscopic areas of necrosis were avoided when drawing
the ROIs, as these were considered to be nonviable tumour
(Figure 1). Since the patient positioning was maintained through-
out each PET scanning sessions, the same ROIs could be applied to
all the dynamic blood flow images and the BV images. The same
ROIs were used for the pre- and post-therapy scan and checked by
visual inspection to ensure that the same area was being analysed
pre- and post-therapy.
For each ROI, the average measured radioactivity concentration
of all pixels within the ROI was computed. In the case of the BV
images, the mean concentration of each ROI was divided by the
mean blood concentration obtained from discrete samples to
determine the fractional BV within the ROI. In the case of the
dynamic blood flow images, the averaged radioactivity in each ROI
was calculated for each time frame to generate mean ROI time–
activity curves. Nonlinear least-squares curve fitting of the ROI
time–activity curves and the measured arterial input function was
carried out using in-house software based on a modified version of
the standard single-tissue compartmental model developed for the
brain (Lammertsma et al, 1985). Parameter estimation of perfusion
and VD were performed using fixed parameter values of delay and
dispersion that were based on previous experiments using the
given blood sampling rate and type and length of tubing. The delay
and dispersion were adjusted manually to provide the best curve
fits of the aorta or spleen and were then fixed for all other tissues.
This resulted in the estimation of perfusion in mlmin
 1ml
 1 and
VD for each tumour and normal tissue ROI sampled. The blood
flow and BV scans were repeated in each session, and so the mean
values were reported and used for all comparisons. The data for
each type of ROI (e.g. tumour, kidney or spleen) were pooled and
the pre- and post-treatment values were compared using a
Student’s paired t-test.
RESULTS
In all, 12 of the Phase II trial patients were enrolled for the PET
study (Table 1), and seven patients were scanned both before and
after treatment with razoxane. Post-treatment scans were not
available on five patients due to symptoms of progressive disease
(four patients) and to reluctance to travel for a second scan (one
patient). Of the 12 patients enrolled, eight metastases and six
primary tumours were scanned (Table 1). The spleen was visibly
definable in three of the patients and normal renal cortex was
definable in eight patients. There were two technical failures of the
Figure 1 A single CT slice across the abdomen on the left and a single slice from a summed PET H2
15O image on the right. Areas of increased brightness
on the PET scan represent increased perfusion (the whiter the area, the higher the perfusion). There is a large right renal mass representing a primary renal
cell carcinoma. This is seen on the PET image as the brighter area with a black centre representing a necrotic core. Vascular structures centrally, such as the
aorta, also are bright.
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lrepeat water scan (one patient) and C
15O scan (one patient) in the
same session. One patient (patient 2) had abnormally high values
for tumour perfusion both pre- and post-treatment. The PET scan
of this patient demonstrated a very high radiotracer concentration
in the tumour mass. The tumour was adjacent to the right renal
hilum. It is probable that the ROI around this tumour mass was
contaminated by surrounding vascular structure, such as the renal
artery or vein. As the model used to calculate perfusion in this
study is not accurate at high flow values, the data for this patient
were excluded from the analysis.
Tumour vascular parameters
Pretreatment tumour vascular parameters varied between the 12
patients, with a mean perfusion of 0.87mlmin
 1ml
 1 (range
0.33–1.67), mean VD of 0.74 (range 0.50–1.11) and mean BV of
0.18 (range 0.08–0.40). Of the six patients who had scans before
and after treatment with razoxane (Table 2), the mean pretreat-
ment perfusion was 0.81mlmin
 1ml
 1 (range 0.46–1.26), while
the mean post-treatment perfusion was 0.72mlmin
 1ml
 1 (range
0.51–1.15). There was a reduction in perfusion following treatment
in two out of six patients (Figure 2), but this did not reach
statistical significance (mean difference¼0.09, P¼0.15). The
mean pretreatment BV was 0.18mlml
 1 (range 0.10–0.25), while
the mean post-treatment BV had virtually no change at
0.17mlml
 1 (range 0.09–0.24, P¼0.55). The mean pretreatment
VD was 0.66 (range 0.50–0.87), while the mean post-treatment VD
was 0.71 (range 0.63–0.82) with a slight increase that was not
statistically significant (P¼0.22).
Relationship of perfusion to tumour size and response
In order to examine for any potential confounding influence of
tumour size on vascular parameters, the relationship between
perfusion and tumour size was assessed using the Spearman
correlation coefficient. There was no statistically significant
correlation between the pretreatment perfusion and size of a
tumour as measured by a CT scan (r¼0.32, n¼13) (Figure 3). The
relationship of tumour perfusion with patient response and
survival was also examined. Of the six patients who had scans
before and after treatment, two patients had stable disease, and
four had progressive disease. The analysis showed no association
between pre- or post-treatment values, or change in perfusion
following treatment, and clinical response at 8 weeks, or best
overall response. There was no statistically significant correlation
between pretreatment perfusion and patient survival following
razoxane administration (r¼0.18, n¼11).
Normal tissue perfusion
Table 1 documents which patients had normal tissue measure-
ments performed, and the data are summarised in Table 2.
Perfusion was lower in tumour compared to the other normal
tissues studied. The perfusion of tumour and normal kidney was
Table 2 Vascular parameters in tumour and normal tissues
Tissue Scanned* Mean perfusion (mlmin
 1ml
 1) (range) Mean VD (range) Mean BV (mlml
 1) (range)
Tumour Pre 0.81 0.66 0.18
(0.46–1.26) (0.50–0.87) (0.10–0.25)
Post 0.72 0.71 0.17
(0.51–1.15) (0.63–0.82) (0.09–0.24)
Spleen Pre 1.14 0.89 0.63
(0.84–1.32) (0.82–0.96) (0.51–0.76)
Post 1.28 0.77 0.54
(0.94–1.62) (0.77–0.78) (0.54–0.55)
Kidney Pre 1.84 0.69 0.17
(1.18–2.88) (0.52–0.78) (0.11–0.20)
Post 1.35 0.71 0.16
(1.16–1.72) (0.42–0.94) (0.09–0.19)
*Scans performed pre- and post-treatment with razoxane. VD¼fractional volume of distribution; BV¼blood volume. There was no statistical difference between pre- and post-
treatment values for perfusion, VD and BV for tumour, spleen or kidney.
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Figure 2 Graph showing perfusion in tumour masses before and after
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was no statistically significant difference in perfusion pre- and post-
treatment with razoxane (P¼0.15).
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Figure 3 Lack of relationship between tumour size (bidimensional area
measured on a CT scan) and tumour perfusion measured by PET (r¼0.32,
n¼13).
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lmeasured during the same scan session in eight patients (Table 3).
A paired t-test comparison of the data showed that the perfusion of
renal cancers was statistically significantly lower than that of
normal kidney tissue (P¼0.0027). In the four patients who had
kidney perfusion measured both before and after treatment with
razoxane, mean pretreatment values were 1.84mlmin
 1ml
 1
(range: 1.18–2.88), while the mean post-treatment values were
1.35mlmin
 1ml
 1 (range: 1.16–1.72). As for tumours, there was a
reduction in post-treatment renal perfusion, but again this did not
reach statistical significance (P¼0.14). Pretreatment BV for renal
cortex was similar to tumours with a mean value of 0.17mlml
 1
(range 0.11–0.20) and a post-treatment mean BV of 0.16mlml
 1
(range 0.09–0.19) with no significant change (P¼0.14). Mean
pretreatment VD was 0.69 (range 0.52–0.78), while there was no
significant change in the post-treatment VD (mean¼0.71, range
0.42–0.94, P¼0.36).
Only two patients had both pre- and post-treatment measure-
ments made in the spleen. Hence, there were insufficient numbers
to perform a statistical analysis. For these two subjects, the
pretreatment perfusion was 1.14mlmin
 1ml
 1 (range 0.84–1.32),
while the post-treatment perfusion was 1.28mlmin
 1ml
 1 (range
0.94–1.62). Pretreatment BV was 0.63mlml
 1 (range 0.51–0.76),
while the post-treatment BV was 0.54mlml
 1 (range 0.54–0.55).
DISCUSSION
This is the one of the first reports of the measurement using PET of
physiological vascular parameters (tumour perfusion, BV and VD)
in patients to assess the effect of a potential antivascular/
antiangiogenic agent in a Phase II study. Results have recently
been reported of a Phase I study of endostatin that incorporated
PET measurements of tumour blood flow (Herbst et al, 2002). In
addition, we have measured vascular changes using PET in a Phase
I study of the vascular targeting agent combretastatin A4
phosphate (Anderson et al, 2003). It should be noted, however,
that the mechanism of action is different for antiangiogenic and
antivascular agents. The former target the formation of new blood
vessels and are expected to require protracted drug administration.
The latter target the existing blood vessels of tumours causing
extensive vascular shutdown and changes in vascular parameters
within hours of administration (Anderson et al, 2003).
One difficulty of assessing the effect of antiangiogenic agents is
that standard measures of tumour response based on volume
change may be inappropriate, as tumour volume is not expected to
change with response. Our hypothesis, based on preclinical data,
was that a course of razoxane would reduce perfusion, BV and VD.
However, we found that in the patients studied, there was no
statistically significant change in vascular parameters after 4–8
weeks of razoxane therapy. Although the lack of control data and
small sample size limit the conclusions that can be drawn from this
study, one interpretation is that a single course of razoxane has no
effect on tumour or normal tissue vasculature in the inoperable
renal cell carcinomas studied.
Nevertheless, the observation of a reduction in perfusion in two
out of six patients (Figure 2) is consistent with the expected
razoxane-induced antiangiogenic effects. It is of interest to note
that the decrease in perfusion was seen in two out of three patients
with high pretreatment tumour perfusion and in zero out of three
patients with low pretreatment perfusion. Whether any threshold
effect is seen for razoxane remains to be established, and requires a
larger study.
A number of observations have emerged from the study that may
be useful for future pharmacodynamic studies of PET vascular
parameters in clinical trials. In this study, renal tumour perfusion
was statistically significantly lower than normal tissue perfusion. In
contrast, perfusion in a series of breast tumours was consistently
higher than in normal breast tissue (Mankoff et al, 2002). The lower
perfusion in tumour vs normal kidney also contrasts with the
observation that levels of the potent proangiogenic protein,
vascular endothelial growth factor (VEGF), are 3–37 times greater
in renal cancer compared to normal parenchyma (Brown et al,
1993). This high level of VEGF in renal tumours is due to
constitutive upregulation because of the stabilisation of the key
transcription factor hypoxia-inducible factor 1a (HIF-1a) (Ohh and
Kaelin, 1999). Hypoxia-inducible factor 1a stabilisation results
from mutations in the von Hippel–Lindau (VHL) gene, which
occur in the majority of clear cell renal cancers (Meyer et al, 2000).
The discrepancy of high angiogenesis but poor perfusion might
result from a greater heterogeneity in the vascularity of tumour vs
normal kidney. Tumours will contain not only ‘hot spots’ of
angiogenesis (Vermeulen et al, 1996), but also poorly perfused
areas that are hypoxic or necrotic. Perhaps future studies of PET
vascular parameters in clinical trials of antiangiogenic agents could
consider defining ROIs only in the most angiogenic areas of
tumours.
Another observation from the study reported here is the lack of
relationship between tumour size and pretreatment perfusion.
Similarly, no statistically significant correlation was reported
between blood flow and size for a series of advanced breast
cancers (Mankoff et al, 2002). Any changes in tumour perfusion
with increasing tumour size might act as a confounding influence
on the ability to measure drug-induced changes in vascular
parameters within clinical trials. The lack of relationship reported
here and elsewhere suggests that inclusion of heterogeneously
sized tumours will not be a limitation in the design of clinical trial
of antiangiogenic agents involving PET measurements of vascular
parameters in renal cell carcinoma. The lack of relationship found
between tumour size and perfusion also suggests that the level of
perfusion in a tumour might be fixed and under genetic rather
than epigenetic control. This genetic control could relate to the
mutational profile of each cancer and the ability of a tumour to
produce angiogenic factors. The suggestion that the level of
perfusion in a tumour is controlled genetically is also consistent
with observations from studies of antiangiogenic therapy. For
example, no reduction of tumour angiogenesis (measure as
microvessel density) was found with the endostatin-induced
shrinkage of an experimental human lung cancer model (Boehle
et al, 2001).
A final observation from the study reported here is that pre- and
post-treatment scans were obtained for only seven out of 12 (58%)
of the patients enrolled for the study. This is lower than the 21 out
of 22 (95%) described for a single-centre Phase I trial (Herbst et al,
2002). As our study involved patient travel to the PET centre, this
observation has implications for the design of future clinical trials
with adequate patient numbers, when patient travel between
centres is required. The small sample size in our study limited the
Table 3 Tumour and normal kidney perfusion in patients who had both
tissues measured in the same scan session
Patient Tumour perfusion
(mlmin
 1ml
 1)
Renal perfusion
(mlmin
 1ml
 1)
3 1.55 2.10
4 0.59 1.35
5 1.26 2.85
7 0.46 1.50
8 1.68 1.55
9 0.72 1.70
10 0.45 1.75
1 1.03 1.65
Mean7s.d. 0.9770.49 1.8170.48*
*P¼0.0027 for a paired t-test comparison of tumour and normal tissue data.
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lability to demonstrate statistically significant razoxane-induced
effects on vascular physiology. Recommendations for the design
of future studies would be to include a sufficient number of
patients to study responders and nonresponders as separate
groups. Furthermore, because the effects of antiangiogenic therapy
are relatively subtle and slow-occurring, there is a general need
for additional control data to understand and quantify the changes
that occur in tumours over time in the absence of treatment.
In summary, the work has shown the feasibility of measuring
PET vascular parameters using H2
15O and C
15O in human renal
cell carcinoma. New drugs are starting to enter clinical trials
that specifically target tumour vasculature, and different methods
are required to assess their effects. This study demonstrates
that PET techniques for measuring physiological vascular para-
meters are a potentially useful tool in this area providing
quantitative data in tumours and normal tissue. The short
half-life of
15O allows multiple measurements within the same
scanning session, which enables multiple assessments and the
study of fast-acting therapies. The study highlights aspects of
vascular physiology of tumours, which are of potential importance
in monitoring new therapies and understanding tumour angio
genesis.
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